Neurology, Vol 45, Issue 7 1305-1308, Copyright © 1995 by American Academy of Neurology

ARTICLES

Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist

J Zoldan, G Friedberg, M Livneh and E Melamed
Department of Neurology, Beilinson Medical Center, Felsenstein Research Institute, Petah Tiqva, Israel.

Psychosis, linked to chronic levodopa and other antiparkinsonian drug treatments, is a common and incapacitating complication of advanced Parkinson's disease (PD). The psychosis may be due, in part, to overstimulation of central serotonergic (5-HT) receptors. We treated 16 PD patients who had psychosis of 6 to 60 months' duration with the 5- HT3 receptor antagonist ondansetron (12 to 24 mg daily) in an open- label, short-term (4 to 8 weeks) trial. There was marked to moderate improvement (p < 0.01) in measures of visual hallucinations, paranoid delusions, confusion, and the associated global functional impairment in all but one of the patients, and there was moderate improvement in the Brief Psychiatric Rating Scale and the Nurse's Observation Scale for Inpatient Evaluation; the Mini-Mental State Examination scores remained unaltered. Ondansetron did not cause any worsening in basic PD symptoms or levodopa efficacy and was well tolerated with no major side effects. Our study suggests that pharmacologic blockade of central 5-HT receptors may become a strategy to attenuate PD psychosis without inducing motor deterioration or suppression of antiparkinsonian action of levodopa, and it lends support to the hypothesis that serotonergic mechanisms are pathogenetically important in the emergence of psychosis in PD.

This article has been cited by other articles:

				J.J. RASIMAS Treatment of Psychosis in Lewy Body Disease Am J Psychiatry, February 1, 2008; 165(2): 261 - 261. [Full Text] [PDF]

				D. WEINTRAUB and H. I. HURTIG Drs. Weintraub and Hurtig Reply Am J Psychiatry, February 1, 2008; 165(2): 261 - 261. [Full Text] [PDF]

				B R Thanvi, T C N Lo, and D P Harsh Psychosis in Parkinson's disease Postgrad. Med. J., October 1, 2005; 81(960): 644 - 646. [Abstract] [Full Text] [PDF]

				D. P. Wint, M. S. Okun, and H. H. Fernandez Psychosis in Parkinson's Disease J Geriatr Psychiatry Neurol, September 1, 2004; 17(3): 127 - 136. [Abstract] [PDF]

				B R Thanvi, S K Munshi, N Vijaykumar, and T C N Lo Neuropsychiatric non-motor aspects of Parkinson's disease Postgrad. Med. J., October 1, 2003; 79(936): 561 - 565. [Abstract] [Full Text] [PDF]

				J. Jankovic Levodopa strengths and weaknesses Neurology, February 1, 2002; 58(90001): S19 - 32. [Abstract] [Full Text]

				C. W. Olanow, R. L. Watts, and W. C. Koller An algorithm (decision tree) for the management of Parkinson's disease (2001):: Treatment Neurology, June 12, 2001; 56(suppl_5): S1 - S88. [Full Text] [PDF]

				C. G. Goetz, P. F. Burke, S. Leurgans, E. Berry-Kravis, L. M. Blasucci, R. Raman, and L. Zhou Genetic Variation Analysis in Parkinson Disease Patients With and Without Hallucinations: Case-Control Study Arch Neurol, February 1, 2001; 58(2): 209 - 213. [Abstract] [Full Text] [PDF]

				C. G. Goetz, L. M. Blasucci, S. Leurgans, and E. J. Pappert Olanzapine and clozapine: Comparative effects on motor function in hallucinating PD patients Neurology, September 26, 2000; 55(6): 789 - 794. [Abstract] [Full Text] [PDF]

				J. M. Miyasaki, D. Grimes, A. E. Lang, S. A. Factor, E. S. Molho, and D. L. Brown Acute delirium after withdrawal of amantadine in Parkinson's disease Neurology, May 1, 1999; 52(8): 1717 - 1717. [Full Text]

				P. De Deurwaerdere, L. Stinus, and U. Spampinato Opposite Change of In Vivo Dopamine Release in the Rat Nucleus Accumbens and Striatum That Follows Electrical Stimulation of Dorsal Raphe Nucleus: Role of 5-HT3 Receptors J. Neurosci., August 15, 1998; 18(16): 6528 - 6538. [Abstract] [Full Text] [PDF]

				J. M Graham, R. A Grunewald, and H. J Sagar Hallucinosis in idiopathic Parkinson's disease J. Neurol. Neurosurg. Psychiatry, October 1, 1997; 63(4): 434 - 440. [Abstract] [Full Text] [PDF]